uniQure N.V.

NasdaqGS QURE

uniQure N.V. EBITDA Margin for the year ending December 31, 2023: -1,597.55%

uniQure N.V. EBITDA Margin is -1,597.55% for the year ending December 31, 2023, a -1,474.85% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

uniQure N.V. EBITDA Margin for the year ending December 31, 2022 was -101.44%, a -266.63% change year over year.
uniQure N.V. EBITDA Margin for the year ending December 31, 2021 was 60.88%, a 117.99% change year over year.
uniQure N.V. EBITDA Margin for the year ending December 31, 2020 was -338.46%, a 78.34% change year over year.
uniQure N.V. EBITDA Margin for the year ending December 31, 2019 was -1,562.85%, a -138.27% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: QURE

uniQure N.V.

CEO	Mr. Christian Klemt
IPO Date	Feb. 5, 2014
Location	Netherlands
Headquarters	Paasheuvelweg 25a
Employees	480
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Key trends

Past 5 years